Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over the Amgen drug that is currently the only approved treatment.
The post After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset appeared first on MedCity News.
